Moloney Securities Asset Management LLC Acquires 6,930 Shares of GRAIL, Inc. (NASDAQ:GRAL)

Moloney Securities Asset Management LLC increased its position in GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 22.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,266 shares of the company's stock after buying an additional 6,930 shares during the quarter. Moloney Securities Asset Management LLC owned about 0.11% of GRAIL worth $977,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. S.A. Mason LLC raised its position in shares of GRAIL by 50.1% during the first quarter. S.A. Mason LLC now owns 1,499 shares of the company's stock worth $38,000 after purchasing an additional 500 shares during the period. KBC Group NV raised its position in shares of GRAIL by 187.7% during the first quarter. KBC Group NV now owns 1,430 shares of the company's stock worth $37,000 after purchasing an additional 933 shares during the period. Caldwell Sutter Capital Inc. acquired a new stake in shares of GRAIL during the first quarter worth $28,000. State of Tennessee Department of Treasury acquired a new stake in shares of GRAIL during the fourth quarter worth $28,000. Finally, Sterling Capital Management LLC acquired a new stake in shares of GRAIL during the fourth quarter worth $29,000.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Canaccord Genuity Group upped their price target on GRAIL from $32.00 to $43.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Morgan Stanley upped their price target on GRAIL from $16.00 to $20.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 18th.

Insider Transactions at GRAIL

In other news, major shareholder Chun R. Ding sold 339,800 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $49.53, for a total transaction of $16,830,294.00. Following the completion of the sale, the insider owned 3,305,055 shares in the company, valued at approximately $163,699,374.15. This represents a 9.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 94,035 shares of the company's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $3,190,607.55. Following the sale, the chief executive officer owned 734,627 shares of the company's stock, valued at approximately $24,925,894.11. This trade represents a 11.35% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 532,890 shares of company stock valued at $23,556,972. 1.85% of the stock is currently owned by company insiders.

GRAIL Trading Down 6.1%

GRAL stock traded down $2.66 during mid-day trading on Friday, hitting $40.73. The stock had a trading volume of 766,643 shares, compared to its average volume of 1,181,230. GRAIL, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99. The company has a fifty day moving average of $41.54 and a 200 day moving average of $33.66. The stock has a market capitalization of $1.47 billion and a price-to-earnings ratio of -0.67.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share for the quarter, topping the consensus estimate of ($4.03) by $0.93. GRAIL had a negative return on equity of 17.99% and a negative net margin of 1,464.53%. The company had revenue of $31.84 million for the quarter, compared to analyst estimates of $35.80 million. As a group, sell-side analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.